The Bitter Fruit with Sweet Health Benefits: A Comprehensive Synopsis of Recent Research Progress on Medicinal Properties of Momordica Charantia

Chapter

Abstract

Though eliciting a somewhat ‘bitter’ taste to our palate, Momordica charantia (MC) is ‘sweet’ for our health. As a popular vegetable indigenous to tropical countries, MC is frequently encountered in the fields of both culinary usage and folklore medicine, especially in Asia. The advance of scientific techniques helps build a platform for investigating the molecular basis of the pharmaceutical functions of medicinal herbs including MC. Over the past few years, a number of pure bioactive components with potential medicinal applications have been procured as a consequence of in vitro and in vivo investigations. In this review, some representative and promising medicinal constituents of MC have been categorized and their emerging medicinal effects such as antitumor, anti-HIV, and anti-diabetic activities are accompanied by the pertinent molecular mechanisms. In addition, the wide range of antimicrobial and pesticidal activities will further validate the medicinal value of MC. Further large-scale clinical trials for those components are needed to fully ascertain their medicinal effects and potential drawbacks, and a new horizon in the treatment of tumor, AIDS, and diabetes may then be opened.

Keywords

Hemagglutinating Activity Ehrlich Ascites Tumor Cell Bitter Gourd Bitter Melon Momordica Charantia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We thank Dr. Jennifer Illuzzi at NIH for her invaluable feedback and critically reading the manuscript. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging, USA.

References

  1. 1.
    Fang EF, Ng TB (2011) Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr Mol Med 11:417–436PubMedCrossRefGoogle Scholar
  2. 2.
    Claflin AJ, Vesely DL, Hudson JL, Bagwell CB, Lehotay DC, Lo TM et al (1978) Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata). Proc Natl Acad Sci U S A 75:989–993PubMedCrossRefGoogle Scholar
  3. 3.
    Wang YX, Neamati N, Jacob J, Palmer I, Stahl SJ, Kaufman JD et al (1999) Solution structure of anti-HIV-1 and anti-tumor protein MAP30: structural insights into its multiple functions. Cell 99:433–442PubMedCrossRefGoogle Scholar
  4. 4.
    Ray RB, Raychoudhuri A, Steele R, Nerurkar P (2010) Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 70:1925–1931PubMedCrossRefGoogle Scholar
  5. 5.
    Fang EF, Zhang CZ, Fong WP, Ng TB (2012) RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis Int J Program Cell Death 17:377–387CrossRefGoogle Scholar
  6. 6.
    Yasui Y, Hosokawa M, Sahara T, Suzuki R, Ohgiya S, Kohno H et al (2005) Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells. Prostaglandins Leukot Essent Fatty Acids 73:113–119PubMedCrossRefGoogle Scholar
  7. 7.
    Agrawal RC, Beohar T (2010) Chemopreventive and anticarcinogenic effects of Momordica charantia extract. Asian Pac J Cancer Prev APJCP 11:371–375Google Scholar
  8. 8.
    Ray RB, Raychoudhuri A, Steele R, Nerurkar P Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 70:1925–1931Google Scholar
  9. 9.
    Lee-Huang S, Huang PL, Sun Y, Chen HC, Kung HF, Murphy WJ (2000) Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. Anticancer Res 20:653–659PubMedGoogle Scholar
  10. 10.
    Pitchakarn P, Ogawa K, Suzuki S, Takahashi S, Asamoto M, Chewonarin T et al (2010) Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci 101:2234–2240PubMedCrossRefGoogle Scholar
  11. 11.
    Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S et al (2009) Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer 125:774–782PubMedCrossRefGoogle Scholar
  12. 12.
    Ru P, Steele R, Nerurkar PV, Phillips N, Ray RB (2011) Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res 4:2122–2130CrossRefGoogle Scholar
  13. 13.
    Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S (2009) Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Br J Nutr 102:1703–1708PubMedCrossRefGoogle Scholar
  14. 14.
    Shih CC, Lin CH, Lin WL (2008) Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract 81:134–143PubMedCrossRefGoogle Scholar
  15. 15.
    Mahomoodally MF, Gurib-Fakim A, Subratty AH Screening for alternative antibiotics: an investigation into the antimicrobial activities of medicinal food plants of Mauritius. J Food Sci 75:M173–177Google Scholar
  16. 16.
    Gupta S, Raychaudhuri B, Banerjee S, Das B, Mukhopadhaya S, Datta SC Momordicatin purified from fruits of Momordica charantia is effective to act as a potent antileishmania agent. Parasitol Int 59:192–197Google Scholar
  17. 17.
    Braca A, Siciliano T, D’Arrigo M, Germano MP (2008) Chemical composition and antimicrobial activity of Momordica charantia seed essential oil. Fitoterapia 79:123–125PubMedCrossRefGoogle Scholar
  18. 18.
    Rajkumar S, Jebanesan A (2007) Repellent activity of selected plant essential oils against the malarial fever mosquito Anopheles stephensi. Trop Biomed 24:71–75PubMedGoogle Scholar
  19. 19.
    Telang M, Srinivasan A, Patankar A, Harsulkar A, Joshi V, Damle A et al (2003) Bitter gourd proteinase inhibitors: potential growth inhibitors of Helicoverpa armigera and Spodoptera litura. Phytochemistry 63:643–652PubMedCrossRefGoogle Scholar
  20. 20.
    Rahuman AA, Venkatesan P (2008) Larvicidal efficacy of five cucurbitaceous plant leaf extracts against mosquito species. Parasitol Res 103:133–139PubMedCrossRefGoogle Scholar
  21. 21.
    Maurya P, Sharma P, Mohan L, Batabyal L, Srivastava CN (2009) Evaluation of larvicidal nature of fleshy fruit wall of Momordica charantia Linn. (family: cucurbitaceae) in the management of mosquitoes. Parasitol Res 105:1653–1659PubMedCrossRefGoogle Scholar
  22. 22.
    Batabyal L, Sharma P, Mohan L, Maurya P, Srivastava CN (2009) Relative toxicity of neem fruit, bitter gourd, and castor seed extracts against the larvae of filaria vector, Culex quinquefasciatus (Say). Parasitol Res 105:1205–1210PubMedCrossRefGoogle Scholar
  23. 23.
    Ling B, Xiang YL, Wang GC, Chen SH, Zhang MX (2009) Antifeedant and antioviposition activities of Momordica charantia leaf ethanol extract against Liriomyza sativae. Ying Yong Sheng Tai Xue Bao 20:836–842PubMedGoogle Scholar
  24. 24.
    Vaya J, Aviram M (2001) Nutritional antioxidants: mechanisms of action, analyses if activities and medical applications. Curr Med Chem Immunol Endocr Metab Agents 1:99–117CrossRefGoogle Scholar
  25. 25.
    Santos AK, Costa JG, Menezes IR, Cansancao IF, Santos KK, Matias EF et al. Antioxidant activity of five Brazilian plants used as traditional medicines and food in Brazil. Pharmacogn Mag 6:335–338Google Scholar
  26. 26.
    Scartezzini P, Speroni E (2000) Review on some plants of Indian traditional medicine with antioxidant activity. J Ethnopharmacol 71:23–43PubMedCrossRefGoogle Scholar
  27. 27.
    Kumar R, Balaji S, Sripriya R, Nithya N, Uma TS, Sehgal PK In vitro evaluation of antioxidants of fruit extract of Momordica charantia L. on fibroblasts and keratinocytes. J Agric Food Chem 58:1518–1522Google Scholar
  28. 28.
    Thenmozhi AJ, Subramanian P (2010) Antioxidant potential of Momordica charantia in Ammonium Chloride-induced Hyperammonemic Rats. Evid Based Complement Alternat Med [Epub ahead of print]Google Scholar
  29. 29.
    Chaturvedi P (2009) Bitter melon protects against lipid peroxidation caused by immobilization stress in albino rats. Int J Vitam Nutr Res 79:48–56PubMedCrossRefGoogle Scholar
  30. 30.
    Ono T, Tsuji T, Sakai M, Yukizaki C, Ino H, Akagi I et al (2009) Induction of hepatocyte growth factor production in human dermal fibroblasts and their proliferation by the extract of bitter melon pulp. Cytokine 46:119–126PubMedCrossRefGoogle Scholar
  31. 31.
    Sonibare MA, Moody JO, Adesanya EO (2009) Use of medicinal plants for the treatment of measles in Nigeria. J Ethnopharmacol 122:268–272PubMedCrossRefGoogle Scholar
  32. 32.
    Alam S, Asad M, Asdaq SM, Prasad VS (2009) Antiulcer activity of methanolic extract of Momordica charantia L. in rats. J Ethnopharmacol 123:464–469PubMedCrossRefGoogle Scholar
  33. 33.
    Fang EF, Zhang CZ, Ng TB, Wong JH, Pan WL, Ye XJ et al (2012) Momordica charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo. Cancer Prev Res 5:109–121CrossRefGoogle Scholar
  34. 34.
    Lin JY, Hou MJ, Chen YC (1978) Isolation of toxic and non-toxic lectins from the bitter pear melon Momordica charantia Linn. Toxicon 16:653–660PubMedCrossRefGoogle Scholar
  35. 35.
    Chandran T, Sharma A, Vijayan M (2010) Crystallization and preliminary X-ray studies of a galactose-specific lectin from the seeds of bitter gourd (Momordica charantia). Acta Crystallogr Sect F Struct Biol Cryst Commun 66:1037–1040PubMedCrossRefGoogle Scholar
  36. 36.
    Tanaka H, Toyama J, Akashi R (2009) Molecular characterization of a galactose-binding lectin from Momordica charantia seeds and its expression in tobacco cells. Asian J Plant Sci 8:544–550CrossRefGoogle Scholar
  37. 37.
    Barbieri L, Zamboni M, Lorenzoni E, Montanaro L, Sperti S, Stirpe F (1980) Inhibition of protein synthesis in vitro by proteins from the seeds of Momordica charantia (bitter pear melon). Biochem J 186:443–452PubMedGoogle Scholar
  38. 38.
    Huang L, Adachi T, Shimizu Y, Goto Y, Toyama J, Tanaka H et al (2008) Characterization of lectin isolated from Momordica charantia seed as a B cell activator. Immunol Lett 121:148–156PubMedCrossRefGoogle Scholar
  39. 39.
    Fang EF, Zhang CZY, Ng TB, Wong JH, Pan WL, Ye XJ et al (2012) Momordica charantia Lectin, a Type II ribosome inactivating Protein, Exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo. Cancer Prev Res 5:109–121CrossRefGoogle Scholar
  40. 40.
    Wang YX, Neamati N, Jacob J, Palmer I, Stahl SJ, Kaufman JD et al (1999) Solution structure of anti-HIV-1 and anti-tumor protein MAP30: structural insights into its multiple functions. Cell 99:433–442PubMedCrossRefGoogle Scholar
  41. 41.
    Yang Y, Mak AN, Shaw PC, Sze KH Solution structure of an active mutant of maize ribosome-inactivating protein (MOD) and its interaction with the ribosomal stalk protein P2. J Mol Biol 395:897–907Google Scholar
  42. 42.
    Lee-Huang S, Huang PL, Nara PL, Chen HC, Kung HF, Huang P et al (1990) MAP 30: a new inhibitor of HIV-1 infection and replication. FEBS Lett 272:12–18PubMedCrossRefGoogle Scholar
  43. 43.
    Fang EF, Zhang CZ, Wong JH, Shen JY, Li CH, Ng TB (2012) The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. Cancer LettGoogle Scholar
  44. 44.
    Fong WP, Mock WY, Ng TB (2000) Intrinsic ribonuclease activities in ribonuclease and ribosome-inactivating proteins from the seeds of bitter gourd. Int J Biochem Cell Biol 32:571–577PubMedCrossRefGoogle Scholar
  45. 45.
    Fong WP, Poon YT, Wong TM, Mock JW, Ng TB, Wong RN et al (1996) A highly efficient procedure for purifying the ribosome-inactivating proteins alpha- and beta-momorcharins from Momordica charantia seeds, N-terminal sequence comparison and establishment of their N-glycosidase activity. Life Sci 59:901–909PubMedCrossRefGoogle Scholar
  46. 46.
    Zhu G, Huang Q, Qian M, Tang Y (2001) Crystal structure of alpha-momorcharin in 80 % acetonitrile–water mixture. Biochim Biophys Acta 1548:152–158PubMedCrossRefGoogle Scholar
  47. 47.
    Tsao SW, Ng TB, Yeung HW (1990) Toxicities of trichosanthin and alpha-momorcharin, abortifacient proteins from Chinese medicinal plants, on cultured tumor cell lines. Toxicon 28:1183–1192PubMedCrossRefGoogle Scholar
  48. 48.
    Ng TB, Liu WK, Sze SF, Yeung HW (1994) Action of alpha-momorcharin, a ribosome inactivating protein, on cultured tumor cell lines. Gen Pharmacol 25:75–77PubMedCrossRefGoogle Scholar
  49. 49.
    Bian X, Shen F, Chen Y, Wang B, Deng M, Meng Y PEGylation of alpha-momorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potential. Biotechnol Lett 32:883–890Google Scholar
  50. 50.
    Yuan YR, He YN, Xiong JP, Xia ZX (1999) Three-dimensional structure of beta-momorcharin at 2.55 A resolution. Acta Crystallogr D Biol Crystallogr 55:1144–1151PubMedCrossRefGoogle Scholar
  51. 51.
    Fukunaga Y, Nishimoto E, Yamashita K, Otosu T, Yamashita S (2007) The partially unfolded state of beta-momorcharin characterized with steady-state and time-resolved fluorescence studies. J Biochem 141:9–18PubMedCrossRefGoogle Scholar
  52. 52.
    Chan WY, Ng TB, Yeung HW (1992) Beta-Momorcharin, a plant glycoprotein, inhibits synthesis of macromolecules in embryos, splenocytes and tumor cells. Int J Biochem 24:1039–1046PubMedCrossRefGoogle Scholar
  53. 53.
    Pu Z, Lu BY, Liu WY, Jin SW (1996) Characterization of the enzymatic mechanism of gamma-momorcharin, a novel ribosome-inactivating protein with lower molecular weight of 11,500 purified from the seeds of bitter gourd (Momordica charantia). Biochem Biophys Res Commun 229:287–294PubMedCrossRefGoogle Scholar
  54. 54.
    Husain J, Tickle IJ, Wood SP (1994) Crystal structure of momordin, a type I ribosome inactivating protein from the seeds of Momordica charantia. FEBS Lett 342:154–158PubMedCrossRefGoogle Scholar
  55. 55.
    Stirpe F, Wawrzynczak EJ, Brown AN, Knyba RE, Watson GJ, Barbieri L et al (1988) Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin. Br J Cancer 58:558–561PubMedCrossRefGoogle Scholar
  56. 56.
    Porro G, Bolognesi A, Caretto P, Gromo G, Lento P, Mistza G et al (1993) In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes. Cancer Immunol Immunother 36:346–350PubMedCrossRefGoogle Scholar
  57. 57.
    Fang EF, Ng TB (1815) Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim Biophys Acta 2011:65–74Google Scholar
  58. 58.
    Ardelt W, Ardelt B, Darzynkiewicz Z (2009) Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol 625:181–189PubMedCrossRefGoogle Scholar
  59. 59.
    Ide H, Kimura M, Arai M, Funatsu G (1991) The complete amino acid sequence of ribonuclease from the seeds of bitter gourd (Momordica charantia). FEBS Lett 289:126PubMedCrossRefGoogle Scholar
  60. 60.
    Numata T, Suzuki A, Kakuta Y, Kimura K, Yao M, Tanaka I et al (2003) Crystal structures of the ribonuclease MC1 mutants N71T and N71S in complex with 5’-GMP: structural basis for alterations in substrate specificity. Biochemistry 42:5270–5278PubMedCrossRefGoogle Scholar
  61. 61.
    Suzuki A, Yao M, Tanaka I, Numata T, Kikukawa S, Yamasaki N et al (2000) Crystal structures of the ribonuclease MC1 from bitter gourd seeds, complexed with 2’-UMP or 3’-UMP, reveal structural basis for uridine specificity. Biochem Biophys Res Commun 275:572–576PubMedCrossRefGoogle Scholar
  62. 62.
    Numata T, Suzuki A, Yao M, Tanaka I, Kimura M (2001) Amino acid residues in ribonuclease MC1 from bitter gourd seeds which are essential for uridine specificity. Biochemistry 40:524–530PubMedCrossRefGoogle Scholar
  63. 63.
    Kimura K, Numata T, Kakuta Y, Kimura M (2004) Amino acids conserved at the C-terminal half of the ribonuclease T2 family contribute to protein stability of the enzymes. Biosci Biotechnol Biochem 68:1748–1757PubMedCrossRefGoogle Scholar
  64. 64.
    Nakagawa A, Tanaka I, Sakai R, Nakashima T, Funatsu G, Kimura M (1999) Crystal structure of a ribonuclease from the seeds of bitter gourd (Momordica charantia) at 1.75 A resolution. Biochim Biophys Acta 1433:253–260PubMedCrossRefGoogle Scholar
  65. 65.
    Fang EF, Ng TB (1815) Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim Biophys Acta-Rev Cancer 2011:65–74Google Scholar
  66. 66.
    Fang EF, Zhang CZ, Zhang L, Fong WP, Ng TB (2012) In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. Int J Biochem Cell Biol 44:1351–1360PubMedCrossRefGoogle Scholar
  67. 67.
    Bennett MK, Kirk CJ (2008) Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel 11:616–625PubMedGoogle Scholar
  68. 68.
    Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U et al (2008) The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 17:879–895PubMedCrossRefGoogle Scholar
  69. 69.
    Kondo H, Nakanose J, Nakagawa A, Tanaka I, Kimura M, Funatsu G (1997) Crystallization and preliminary X-ray studies of two serine proteinase inhibitors, BGIA and BGIT, from the seeds of bitter gourd. J Struct Biol 120:204–206PubMedCrossRefGoogle Scholar
  70. 70.
    Hamato N, Koshiba T, Pham TN, Tatsumi Y, Nakamura D, Takano R et al (1995) Trypsin and elastase inhibitors from bitter gourd (Momordica charantia LINN.) seeds: purification, amino acid sequences, and inhibitory activities of four new inhibitors. J Biochem 117:432–437PubMedCrossRefGoogle Scholar
  71. 71.
    Zhu Y, Huang Q, Qian M, Jia Y, Tang Y (1999) Crystal structure of the complex formed between bovine beta-trypsin and MCTI-A, a trypsin inhibitor of squash family, at 1.8-A resolution. J Protein Chem 18:505–509PubMedCrossRefGoogle Scholar
  72. 72.
    Fang EF, Wong JH, Ng TB Thermostable Kunitz trypsin inhibitor with cytokine inducing, antitumor and HIV-1 reverse transcriptase inhibitory activities from Korean large black soybeans. J Biosci Bioeng 109:211–217Google Scholar
  73. 73.
    Losso JN (2008) The biochemical and functional food properties of the bowman-birk inhibitor. Crit Rev Food Sci Nutr 48:94–118PubMedCrossRefGoogle Scholar
  74. 74.
    Drag M, Salvesen GS Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 9:690–701Google Scholar
  75. 75.
    Tan MJ, Ye JM, Turner N, Hohnen-Behrens C, Ke CQ, Tang CP et al (2008) Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 15:263–273PubMedCrossRefGoogle Scholar
  76. 76.
    Popovich DG, Li L, Zhang W Bitter melon (Momordica charantia) triterpenoid extract reduces preadipocyte viability, lipid accumulation and adiponectin expression in 3T3-L1 cells. Food Chem Toxicol 48:1619–1626Google Scholar
  77. 77.
    Akihisa T, Higo N, Tokuda H, Ukiya M, Akazawa H, Tochigi Y et al (2007) Cucurbitane-type triterpenoids from the fruits of Momordica charantia and their cancer chemopreventive effects. J Nat Prod 70:1233–1239PubMedCrossRefGoogle Scholar
  78. 78.
    Li QY, Chen HB, Liu ZM, Wang B, Zhao YY (2007) Cucurbitane triterpenoids from Momordica charantia. Magn Reson Chem 45:451–456PubMedCrossRefGoogle Scholar
  79. 79.
    Nhiem NX, Kiem PV, Minh CV, Ban NK, Cuong NX, Tung NH et al Alpha-Glucosidase inhibition properties of cucurbitane-type triterpene glycosides from the fruits of Momordica charantia. Chem Pharm Bull (Tokyo) 58:720–724Google Scholar
  80. 80.
    Chang CI, Chen CR, Liao YW, Shih WL, Cheng HL, Tzeng CY et al Octanorcucurbitane triterpenoids protect against tert-butyl hydroperoxide-induced hepatotoxicity from the stems of Momordica charantia. Chem Pharm Bull (Tokyo) 58:225–229Google Scholar
  81. 81.
    Chen JC, Liu WQ, Lu L, Qiu MH, Zheng YT, Yang LM, Kuguacins F-S et al (2009) Cucurbitane triterpenoids from Momordica charantia. Phytochemistry 70:133–140Google Scholar
  82. 82.
    Chen J, Tian R, Qiu M, Lu L, Zheng Y, Zhang Z (2008) Trinorcucurbitane and cucurbitane triterpenoids from the roots of Momordica charantia. Phytochemistry 69:1043–1048PubMedCrossRefGoogle Scholar
  83. 83.
    Mekuria DB, Kashiwagi T, Tebayashi S, Kim CS (2006) Cucurbitane glucosides from Momordica charantia leaves as oviposition deterrents to the leafminer. Liriomyza trifolii. Z Naturforsch C 61:81–86Google Scholar
  84. 84.
    Vashishta A, Sahu T, Sharma A, Choudhary SK, Dixit A (2006) In vitro refolded napin-like protein of Momordica charantia expressed in Escherichia coli displays properties of native napin. Biochim Biophys Acta 1764:847–855PubMedCrossRefGoogle Scholar
  85. 85.
    Neumann GM, Condron R, Polya GM (1996) Purification and sequencing of napin-like protein small and large chains from Momordica charantia and Ricinus communis seeds and determination of sites phosphorylated by plant Ca(2 +)-dependent protein kinase. Biochim Biophys Acta 1298:223–240PubMedCrossRefGoogle Scholar
  86. 86.
    Khanna P, Jain SC, Panagariya A, Dixit VP (1981) Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 44:648–655PubMedCrossRefGoogle Scholar
  87. 87.
    Kelley LA, Sternberg MJ (2009) Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 4:363–371PubMedCrossRefGoogle Scholar
  88. 88.
    Takemoto DJ, Jilka C, Rockenbach S, Hughes JV (1983) Purification and characterization of a cytostatic factor with anti-viral activity from the bitter melon. Prep Biochem 13:371–393PubMedCrossRefGoogle Scholar
  89. 89.
    Nerurkar P, Ray RB Bitter melon: antagonist to cancer. Pharm Res 27:1049–1053Google Scholar
  90. 90.
    Grover JK, Yadav SP (2004) Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol 93:123–132PubMedCrossRefGoogle Scholar
  91. 91.
    Parkash A, Ng TB, Tso WW (2002) Purification and characterization of charantin, a napin-like ribosome-inactivating peptide from bitter gourd (Momordica charantia) seeds. J Pept Res 59:197–202PubMedCrossRefGoogle Scholar
  92. 92.
    Ren J, Wang Y, Dong Y, Stuart DI (1994) The N-glycosidase mechanism of ribosome-inactivating proteins implied by crystal structures of alpha-momorcharin. Structure 2:7–16PubMedCrossRefGoogle Scholar
  93. 93.
    Xiong JP, Xia ZX, Zhang L, Ye GJ, Jin SW, Wang Y (1994) Crystallization and preliminary crystallographic study of beta-momorcharin. J Mol Biol 238:284–285PubMedCrossRefGoogle Scholar
  94. 94.
    Fang EF, Ng TB (2011) Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim Biophys Acta-Rev Cancer 1815:65–74Google Scholar
  95. 95.
    Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC et al (2004) UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.School of Life Sciences, Faculty of ScienceThe Chinese University of Hong KongShatinHong Kong
  2. 2.Laboratory of Molecular GerontologyNational Institute on Aging, National Institutes of HealthBaltimoreUSA

Personalised recommendations